This may be because Aβ and combined Aβ/tau pathology are strong predictors of clinical decline and conversion to AD, whereas tau is associated with other pathologies, and is therefore not an ideal single marker for the prediction of specific dementia types. This evidence concerns the gene MAPT and dementia.